Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18.
Adolescent
Capsid Proteins
/ genetics
Cross Protection
/ genetics
Cross-Sectional Studies
Female
Genotype
Human papillomavirus 16
/ genetics
Human papillomavirus 18
/ genetics
Humans
Netherlands
Papanicolaou Test
Papillomavirus Infections
/ prevention & control
Papillomavirus Vaccines
/ immunology
Phylogeny
Polymerase Chain Reaction
Treatment Outcome
Vaginal Smears
Young Adult
HPV
bivalent vaccine
cross-protection
papillomavirus
phylogeny
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
30 08 2019
30 08 2019
Historique:
received:
15
03
2019
accepted:
03
06
2019
pubmed:
6
6
2019
medline:
28
5
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18.
Identifiants
pubmed: 31165164
pii: 5511346
doi: 10.1093/infdis/jiz280
pmc: PMC6736382
doi:
Substances chimiques
Capsid Proteins
0
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1141-1146Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Immunol. 2009 Nov 15;183(10):6186-97
pubmed: 19864596
Mol Biol Evol. 2013 May;30(5):1188-95
pubmed: 23418397
Virology. 2013 Oct;445(1-2):2-10
pubmed: 23683837
BMJ Open. 2016 Feb 11;6(2):e009915
pubmed: 26868944
Expert Rev Vaccines. 2016;15(3):367-87
pubmed: 26902666
Br J Cancer. 2016 May 24;114(11):1261-4
pubmed: 27115467
Nucleic Acids Res. 2017 Jan 4;45(D1):D499-D506
pubmed: 28053164
J Infect. 2017 Apr;74(4):393-400
pubmed: 28126492
Gynecol Oncol. 2017 Jul;146(1):196-204
pubmed: 28442134
Lancet Infect Dis. 2017 Dec;17(12):1293-1302
pubmed: 28965955
J Infect Dis. 2018 Jan 4;217(2):213-222
pubmed: 29140439
Int J Cancer. 2018 Jun 15;142(12):2491-2500
pubmed: 29377141
J Infect Dis. 2018 Apr 23;217(10):1579-1589
pubmed: 29409034
Nat Rev Cancer. 2018 Apr;18(4):240-254
pubmed: 29497146
PLoS One. 2019 Mar 4;14(3):e0212927
pubmed: 30830913